Introduction to a special edition in Steroids of nuclear hormone receptor modulators
The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators
Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential
From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs) ☆,☆☆
Nuclear receptor modulation – Role of coregulators in selective estrogen receptor modulator (SERM) actions
Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations
Menopausal hormone therapy and cancer: Changing clinical observations of target site specificity
Selective estrogen-induced apoptosis in breast cancer
Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss
Ospemifene: A first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy
Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer